MS Drug To Treat Chemo Neuropathy

Today's post from sciencedaily.com (see link below) talks about the danger of chemotherapy drugs causing neuropathy but also looks at an option to address that threat by using a drug normally used for Multiple Sclerosis. Unfortunately, cancer is more common these days due partly to our increasing age and partly to unwise lifestyle choices. Chemotherapy remains the standard treatment for tumors and as a result, the number of people suffering from neuropathy as a side effect is also increasing exponentially. The chemotherapy drugs most likely to cause neuropathy come from the Taxanes family of drugs but unfortunately, these are also the most effective in treating the cancer. It's a bit of a Catch22 situation but hopefully, progress will be made with this MS option to counteract the threat.

Possible answer to chemo pain found in multiple sclerosis drug
Date: June 23, 2014 Source: Saint Louis University 

Summary:

Two discoveries have been described by researchers: a molecular pathway by which a painful chemotherapy side effect happens and a drug that may be able to stop it. "The chemotherapy drug paclitaxel is widely used to treat many forms of cancer, including breast, ovarian and lung cancers," said one researcher. "Though it is highly effective, the medication, like many other chemotherapy drugs, frequently is accompanied by a debilitating side effect called chemotherapy induced peripheral neuropathy, or CIPN."

In a recently published study in the Journal of Biological Chemistry, Saint Louis University professor of pharmacological and physiological sciences Daniela Salvemini, Ph.D. describes two discoveries: a molecular pathway by which a painful chemotherapy side effect happens and a drug that may be able to stop it.

"The chemotherapy drug paclitaxel is widely used to treat many forms of cancer, including breast, ovarian and lung cancers," said Salvemini. "Though it is highly effective, the medication, like many other chemotherapy drugs, frequently is accompanied by a debilitating side effect called chemotherapy induced peripheral neuropathy, or CIPN."

CIPN can appear as tingling or numbness in the hands and feet, shooting or burning pain in the limbs, or can feel like hot or cold temperature extremes. Symptoms may resolve within weeks or months of stopping the chemotherapy treatment or may last for years. In addition to causing patients suffering, CIPN is often a limiting factor when it comes to treatment.

Physicians estimate that CIPN can occur in 30 to 90 percent of patients treated with taxanes (the class of drugs that includes paclitaxel) and combination chemotherapies.

Salvemini and her colleagues studied paclitaxel, which also is known as Taxol, and discovered that the pain pathway (the series of interactions between molecular-level components) is dependent on activation of sphingosine 1-phosphate receptor subtype 1 (S1PR1) in the central nervous system by engaging a series of damaging neuro-inflammatory processes leading to pain. By inhibiting this molecule, they found that they could block and reverse paclitaxel-induced neuropathic pain without interfering with the drug's anticancer effects.

This finding is particularly encouraging because a drug that modulates S1PR1 is already on the market. A medication called FTY720 (Gilenya) is FDA-approved as a therapy for multiple sclerosis. When Salvemini tested this drug in her lab, she found that the S1PR1 modulator weakened the neuroinflammatory processes, which in turn blocked and reversed neuropathic pain without altering the anticancer properties of paclitaxel. Further, the beneficial effects of FTY720 were not restricted to paclitaxel but also extended to another chemotherapeutic agent, the platinum based drug oxaliplatin which is widely used for metastatic colon cancer and other gastrointestinal cancers.

While clinical trials will be necessary to determine the safety and efficacy of the drug in treating CIPN, researchers are hopeful that they may be able not only to relieve cancer patients of debilitating pain, but also save more lives by permitting the administration of larger, potentially more effective doses of chemotherapy drugs.

"We have identified a critical pathway by which CIPN develops and continues that can be targeted with a drug that is already FDA approved. This does not happen often," said Salvemini. "We need to capitalize on these findings and explore use of these agents in cancer pain patients to improve quality of life and potentially maximize anticancer efficacy as soon as possible."

Story Source:

The above story is based on materials provided by Saint Louis University. The original article was written by Carrie Bebermeyer. Note: Materials may be edited for content and length.

Journal Reference:
K. Janes, J. W. Little, C. Li, L. Bryant, C. Chen, Z. Chen, K. Kamocki, T. Doyle, A. Snider, E. Esposito, S. Cuzzocrea, E. Bieberich, L. Obeid, I. Petrache, G. Nicol, W. L. Neumann, D. Salvemini. The Development and Maintenance of Paclitaxel-Induced Neuropathic Pain Requires Activation of the Sphingosine 1-Phosphate Receptor Subtype 1. Journal of Biological Chemistry, 2014; DOI: 10.1074/jbc.M114.569574 

 http://www.sciencedaily.com/releases/2014/06/140623131335.htm